India’s pharmaceutical exports reached $5.29 billion in April-May, growing 6.6% despite declining demand in the US and the West Asia region. Strong vaccine shipments and growth in European and ASEAN markets offset the weakness in these key territories.
What Happened
India’s pharmaceutical sector reported a 6.63% increase in total exports, reaching $5.29 billion during April and May 2026. This growth occurred despite a notable decline in demand from the United States and the West Asia North Africa (WANA) region. Shipments to the US, which typically account for nearly 30% of India's total pharmaceutical exports, fell by 6.31% to $1.6 billion. Similarly, exports to the WANA region contracted by 0.37%. These two areas were the only major regions to report negative growth, marking a continuation of trends seen in the previous fiscal year.
Diversification and Growth Drivers
While key markets struggled, other regions helped maintain positive momentum. Vaccine exports were a significant contributor, surging by 37.47% during the two-month period. Other areas such as the ASEAN bloc, Latin America, Africa, and Europe also recorded double-digit growth, ranging from 13% to 27%. Drug formulations and biological products, which represent the largest share of Indian exports at approximately 74%, saw a steady increase of 4.04%. Additionally, the segment for bulk drugs and intermediates expanded by 13.59%, providing further support to the overall export value.
Why Investors Should Note the US Market Shift
The United States remains the most critical market for Indian pharmaceutical companies due to its size and the premium nature of generic drugs sold there. The ongoing decline in US exports suggests that companies may be facing sustained pricing pressure or regulatory hurdles that limit market access. For investors, this highlights the importance of market diversification. Companies that have successfully expanded their presence in Europe, the UK, and emerging markets like Brazil may be better positioned to mitigate the risks associated with the US slowdown.
Sectoral Realities and Risks
The decline in exports to the WANA region has been linked to disruptions from ongoing regional geopolitical tensions, which can complicate supply chains and payment cycles. While overall growth remains positive, investors may track whether Indian manufacturers can maintain their profit margins as they pivot toward secondary markets. These new markets often have different regulatory requirements and price points compared to the US, which can impact the profitability of specific product portfolios.
What Investors Should Track
The key monitorables for the sector in the coming quarters include the stability of vaccine export demand and whether the contraction in the US market begins to stabilize. Investors may also monitor upcoming quarterly results from major pharmaceutical companies to see how the mix of geographic sales is affecting individual company margins. Additionally, any updates on regulatory approvals for new product launches in the US or expanded presence in regions like China or Europe will provide insight into the industry's ability to maintain long-term growth.